As sustainability pressures intensify across healthcare, one often-overlooked component is taking center stage: the propellant inside metered dose inhalers (MDIs). While invisible to patients, these propellants account for up to 95% of an inhaler’s formulation—and a significant share of its environmental footprint.
Andy Burns, Vice President of Business Development for MDI at Kindeva, a drug delivery CDMO that specializes in injectable, inhalation, and dermal products, explains what’s driving the shift,and what it means for pharma and packaging stakeholders.
Follow this podcast on your favorite streaming platform - links can be found by clicking here.
Companies in this podcast
